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ABSTRACT: Species in the Juncaceae accumulate different types
of secondary metabolites, among them phenanthrenes and 9,10-
dihydrophenanthrenes in substantial amounts. These compounds
have chemotaxonomic significance and also possess interesting
pharmacological activities. The present study has focused on the
isolation, structure determination, and pharmacological inves-
tigation of phenanthrenes from Juncus gerardii. Twenty-six
compounds, including 23 phenanthrenes, have been isolated
from a methanol extract of this plant. Twelve compounds, the
phenanthrenes gerardiins A−L (1−12), were obtained as new
natural products. Eleven phenanthrenes [effusol (13), dehydroef-
fusol (14), effususin A (15), compressin A, 7-hydroxy-2-methoxy-
1-methyl-5-vinyl-9,10-dihydrophenanthrene, juncusol, 2-hydroxy-
7-hydroxymethyl-1-methyl-5-vinyl-9,10-dihydrophenanthrene, 2,7-dihydroxy-5-formyl-1-methyl-9,10-dihydrophenanthrene, effusu-
sol A, 2,7-dihydroxy-5-hydroxymethyl-1-methyl-9,10-dihydrophenanthrene, and jinflexin C], 1-O-p-coumaroyl-3-O-feruloyl-glycerol,
and the flavones apigenin and luteolin were isolated for the first time from this plant. The cytotoxicity of the 23 isolated
phenanthrenes in both mouse (4T1) and human (MDA-MB-231) triple-negative breast cancer cells and in a nontumor (D3, human
cerebral microvascular endothelial) cell line was tested using an MTT viability assay. The results obtained showed that the dimeric
compounds gerardiins I (9), J (10), K (11), and L (12), derived biogenetically from effusol and dehydroeffusol, were cytotoxic to
both tumor and nontumor cell lines, while the monomeric compounds exerted no or very low cytotoxicity. Impedance
measurements were consistent with the results of the MTT assays performed.
The plant family Juncaceae is an abundant source ofphenanthrene derivatives. These compounds can be
found in almost all parts (e.g., roots, medulla, leaves) of the
plants belonging to this family.1 In terms of biosynthesis,
phenanthrenes and dihydrophenanthrenes are classified as
stilbenoids, with 9,10-dihydrophenanthrenes being formed
from bibenzyls by an oxidative coupling reaction. These
compounds are thus products of the phenylpropanoid
metabolism in combination with polyketide formation.
Phenanthrenes are synthesized by stilbene synthase from
cinnamic acids through stilbene precursors.2 The biosynthesis
of these compounds can be enhanced by different stress
conditions, such as fungal infection or wounds or by increases
in the salt concentration of the soil.3
Phenanthrenes occurring in Juncaceae species have chemo-
taxonomic significance, as several of them contain a vinyl group
in the molecule. To date, almost 100 monomers and dimers,
substituted with methyl, hydroxy, vinyl, methoxy, oxy-
methylene, methoxyethyl, ethoxyethyl, and formyl groups,
have been isolated from different Juncus and Luzula species.1
Phenanthrenes possess a wide range of biological activities,
including antimicrobial, antiproliferative, anti-inflammatory,
anxiolytic, and spasmolytic effects.4
In a continuation of our work aiming at the isolation of
biologically active compounds from Juncaceae species, the
halophyte plant Juncus gerardii Loisel. was investigated.
Halophytes are specialized plants able to survive and thrive
in saline soils. Apart from their physiological adaptation,
improved biochemical strategies such as improved antioxidant
capacity and transporters determine the tolerance against
oxidative stress caused by high salinity conditions.5 Moreover,
these antioxidant systems, including enzymes and bioactive
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compounds, produce a plethora of further interesting bio-
logical activities.6
The phytochemistry and pharmacology of J. gerardii have
not been previously investigated. The isolation procedure was
carried out by using combined chromatographic methods. The
structures of the isolated compounds were elucidated by 1D
and 2D NMR spectroscopic and HRMS methods. Twenty-six
compounds were obtained, including 23 phenanthrenes, a
glycerol derivative, and two flavonoids. Twelve phenanthrenes,
named as gerardiins A−L (1−12), were new natural products.
The isolated phenanthrenes were tested for their cytotoxic
activity against three different cell lines.
■ RESULTS AND DISCUSSION
The dried and ground whole plant material (3.6 kg) was
extracted with methanol at room temperature. After evapo-
ration, the extract was dissolved in 50% aqueous methanol, and
solvent−solvent partition was performed with n-hexane,
chloroform, and EtOAc. The chloroform and EtOAc phases
were purified by a combination of different techniques,
including CC, VLC, MPLC, gel filtration, preparative TLC,
and HPLC, to afford 26 compounds. The structure
determinations for the new compounds were carried out by
spectroscopic data analysis, using 1D (1H, JMOD) and 2D
NMR (1H−1H COSY, HSQC, HMBC, NOESY) spectrosco-
py, HRESIMS measurement, and comparison of the
spectroscopic data obtained with reported literature values
for related compounds.
Compound 1 was obtained as an amorphous solid. Its
HRESIMS provided the molecular formula C18H18O3 through
the presence of a peak at m/z 251.1068 ([M + H − CH3OH]+,
calcd C17H18O2, 251.1072). The
1H NMR spectrum (Table 1)
displayed signals of two ortho- (δH 6.69 and 7.32, each 1H, d, J
= 8.5 Hz) and two meta-coupled (δH 6.64 and 6.84, each 1H,
d, J = 2.4 Hz) aromatic protons, three methylenes (δH 2.62,
2.75 m, and 4.65 s, each 2H), a vinyl moiety (δH 6.91, 5.21,
and 5.65, each 1H, dd), and a methoxy group (δH 3.40, 3H, s).
The JMOD spectrum contained 18 carbon resonances
attributable to a vinyl- and methoxy-substituted phenanthrene
derivative (Table 1). The presence of two adjacent methylene
signals (H2-9, H2-10) in the COSY spectrum suggested that
compound 1 is a 9,10-dihydrophenanthrene derivative. Further
COSY correlations were observed between the signals at δH
6.69 and δH 7.32 (H-3/H-4), as well as δH 6.91 and δH 5.21
and 5.65 (H-12/H-13). The connectivities of the COSY
fragments were determined by means of relevant HMBC
correlations (Figure 1).
Heteronuclear long-range correlations of C-4a with H-3 and
H2-10, C-5a with H-4, H-6, H-8, and H2-9, C-1a with H-4, H2-
9, and H2-11, C-9 with H-8, and C-8a with H2-10 were used to
establish a 9,10-dihydrophenanthrene skeleton for compound
1. HMBC cross-peaks of C-2 (δC 156.0) with H-3, H-4, and
H2-11, together with C-7 (δC 156.7) with H-6 and H-8,
showed the presence of two hydroxy groups at C-2 and C-7.
The vinyl moiety was placed at C-5 based on the C-5a/H-12,
C-6/H-12, and C-5/H2-13 correlations. In addition, the strong
cross-peak of the methoxy group and the hydroxymethylene at
δC 66.5 confirmed its location on C-11. The NOE interactions
of H-4/H-12, H-8/H2-9, and H2-10/H2-11 corroborated the
proposed structure of gerardiin A (1), as shown.
Compound 2 (gerardiin B) was obtained as an amorphous
solid. The HRESIMS peak at m/z 249.1275 established the
molecular formula as C19H20O2 ([M + H − CH3OH]+, calcd
C18H17O, 249.1279). In the
1H NMR spectrum, signals of a
methyl group (δH 2.18, 3H, s), four ortho-coupled aromatic
protons (δH 7.53 and 7.25, each 1H, d, J = 8.0 Hz, 7.43 and
6.72, each 1H, d, J = 8.5 Hz), and a vinyl group (δH 6.85, 5.57,
and 5.25, each 1H, dd, J = 17.4 and 10.8 Hz, 17.4 and 1.3 Hz,
and 10.8 and 1.3 Hz, respectively) were observed (Table 1).
The presence of saturated methylene protons at δH 2.70 and
2.82 (each 2H, m) indicated this compound to be a 9,10-
dihydrophenanthrene. The HMBC cross-peaks C-7/H-5, C-
8a/H-5, C-8/H-6, C-12/H-6, C-8/H2-12, C-7/H2-12, C-7/H-
13, C-8a/H-13, and C-8/H-14 demonstrated that the oxy-
methylene and vinyl groups are situated on the adjacent
carbons C-7 and C-8, respectively. The three-bond correlation
of the methoxy group with the carbon resonating at δC 74.3
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unambiguously showed that it is attached to C-12. NOE
correlations of H-4/H-5, H-6/H2-12, H2-12/H-14b, H2-9/H-
13, and H2-10/H3-11 supported the above findings and
afforded the structure of gerardiin B (2), as shown.
According to the sodiated molecular ion exhibited at m/z
437.1565 [M + Na]+ in the HRESIMS spectrum, compound 3
(gerardiin C) has the molecular formula C23H26O7 (calcd
C23H26O7Na, 437.1576). The
1H NMR spectrum contained
the signals of two ortho- (δH 7.18 and 7.00, each 1H, d, J = 8.6
Hz) and two meta-coupled (δH 6.80, 1H, d, J = 2.2 Hz and
6.66, 1H, br s) aromatic methines, a vinyl group (δH 6.84, 1H,
dd, J = 17.3 and 10.8 Hz, and 5.64 and 5.27, each 1H, d, J =
17.3 and 10.8 Hz, respectively), and a methyl group (δH 2.21,
3H, s), two methylenes (δH 2.64 and 2.59, each 2H, m), and a
sugar moiety. The monosaccharide was identified as D-glucose
based on its 1H and 13C chemical shift values. The large
coupling constant of the anomeric H-1′ proton (J = 7.1 Hz)
indicated that the glucose unit is attached to the phenanthrene
skeleton through a β-glycosidic bond. The 1D and 2D NMR
data of compound 3 were similar to those of effusol, and the
HMBC cross-peaks C-2/H-4, C-2/H3-11, and C-2/H-1′
revealed that gerardiin C (3) is a 2-O-glycoside of a known
aglycon, as shown.
The same molecular formula, C23H26O7 (m/z 437.1564 [M
+ Na]+, calcd C23H26O7Na, 437.1576), was assigned to
gerardiin D (4) as to 3, suggesting that these compounds are
structural isomers. The markedly upfield shifted H-3 (δH 6.72,
1H, d, J = 8.4 Hz vs 7.00, 1H, d, J = 8.6 Hz in 3) and the
deshielded meta-coupled protons assigned to ring C (δH‑6 7.06
and δH‑8 6.92, each 1H, d, J = 2.1 Hz vs 6.80, 1H, d, J = 2.2 Hz,
and 6.66, 1H, br s in 3) implied that the glucose unit is
attached to the C-7 hydroxy group of the aglycone (Table 2).
This conclusion was confirmed by HMBC cross-peaks between
C-7 (δC 155.4), H-6, and H-8, as well as by the NOE
interactions of H-6 and H-8 with H-1′, with the structure
proposed for 4 as shown.
Compound 5 (gerardiin E) was obtained as a colorless,
amorphous solid. Its molecular formula was determined as
C17H18O3 by the HRESIMS data (m/z 253.1226 [M + H −
H2O]
+, calcd C17H17O2, 253.1229). The presence of four
aromatic methines (two meta- and two ortho-coupled), two
saturated methylenes, and one methyl group in the 1H NMR
spectrum revealed that 5 is a 1,2,5,7-tetrasubstituted 9,10-
dihydrophenanthrene derivative (Table 2). However, the lack
of any characteristic resonances of a vinyl moiety, and the
Table 1. 1H (500 MHz) and 13C (125 MHz) NMR Data of Compounds 1−3
1a 2a 3b
position δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type
1 121.8, C 122.3, C 123.5, C
1a 142.2, C 137.2, Cc 138.3, C
2 156.0, C 156.2, C 154.2, C
3 6.69, d (8.5) 112.9, CH 6.72, d (8.5) 114.0, CH 7.00, d (8.6) 111.7, CH
4 7.32, d (8.5) 131.1, CH 7.43, d (8.5) 123.5, CH 7.18, d (8.6) 126.5, CH
4a 127.4, C 127.7, C 127.4, C
5 137.3, C 7.53, d (8.0) 123.1, CH 135.7, C
5a 127.2, C 136.8, C 124.9, C
6 6.84, d (2.4) 113.6, CH 7.25, d (8.0) 128.6, CH 6.80, d (2.2) 112.6, CH
7 156.7, C 134.3, C 155.8, C
8 6.64, d (2.4) 115.0, CH 138.5, Cc 6.66, br s 114.3, CH
8a 141.8, C 135.1, C 140.3, C
9 2.62, m 31.4, CH2 2.82, m 27.1, CH2 2.59, m 29.7, CH2
10 2.75, m 26.5, CH2 2.70, m 26.2, CH2 2.64, m 25.1, CH2
11 4.65, s 66.5, CH2 2.18, s 11.6, CH3 2.21, s 11.9, CH3
OCH3-11 3.40, s 58.1, CH3
12 6.91, dd (17.4, 10.8) 140.2, CH 4.44, s 74.3, CH2 6.84, dd (17.3, 10.8) 138.4, CH
OCH3-12 3.36, s 58.1, CH3
13 5.65, dd (17.4, 1.3) 113.9, CH2 6.85, dd (17.9, 11.5) 135.4, CH 5.64, d (17.3) 114.1, CH2
5.21, dd (10.8, 1.3) 5.27, d (10.8)
14 5.57, dd (11.5, 2.1) 120.9, CH2
5.25, dd (17.9, 2.1)
1′ 4.79, d (7.1) 101.3, CH
2′ 3.28, m 73.4, CH
3′ 3.26, m 76.7, CH
4′ 3.16, m 69.8, CH
5′ 3.31, m 77.1, CH
6′ 3.70, br d (11.4) 60.8, CH2
3.46, m
aMeasured in MeOD. bMeasured in DMSO-d6.
cInterchangeable signals.
Figure 1. 1H−1H COSY (red) and diagnostic HMBC (C→H)
correlations of 1.
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additional oxymethine and methyl signals detected at δH 5.05
(1H, q, J = 6.2 Hz) and δH 1.39 (3H, d, J = 6.2 Hz), suggested
the presence of an α-hydroxyethyl group in the molecule.
HMBC cross-peaks of C-12 (δC 64.2) with H-6 (δH 6.92), C-
5a (δC 124.8) with H-4 (δH 7.13), H-6, and H-12 (δH 5.05),
and C-5 (δC 144.2) with H-12 and H3-13 (δH 1.39) revealed
that the hydroxyethyl substituent is attached to C-5. From a
biosynthetic point of view, this side chain is most likely formed
from a vinyl group through hydration of the vinylic double
bond. NOEs between H-4, H-12, and H3-13, as well as
between H-6 and H3-13, were in line with the proposed
structure of gerardiin E (5), as shown.
The molecular formula C23H28O8 of gerardiin F (6) was
deduced from the sodium adduct ion [M + Na]+ observed at
m/z 455.1671 (calcd C23H28O8Na, 455.1682) in the
HRESIMS. Apart from the signals of a D-glucose moiety, the
1H NMR data closely resembled those of compound 5. On
examining the chemical shifts, the deshielded nature of H-3
and H-4 (δH 7.00 and 7.26, each 1H, d, J = 8.6 Hz in 6 vs 6.71
and 7.13, each 1H, d, J = 8.4 Hz in 5) clearly suggested that the
sugar unit is attached to the skeleton at C-2 (δC 153.9) (Table
2). The position of the β-D-glucose was substantiated by
HMBC correlations of C-2 (δC 153.9) with H-4, H3-11, and
the anomeric H-1′ and by the NOE cross-peak between H-3/
H-1′, and the structure of 6 was proposed as shown.
Gerardiin G (7) was shown to be a structural isomer of 6 by
the sodium adduct HRESIMS ion at m/z 455.1675 [M + Na]+
(calcd C23H28O8Na, 455.1682). As in the case of gerardiin D,
the position of the β-D-glucose at C-7 (δC 155.5) was
determined with the aid of diagnostic HMBC and NOE cross-
peaks, leading to the structure of 7 as shown.
HRESIMS data provided the molecular formula of C18H16O
for gerardiin H (8) through the presence of a peak at m/z
249.1274 ([M + H]+, calcd C18H17O, 249.1279). The
1H
NMR data of 8 were similar to those of the known 9,10-
dehydrophenanthrene juncunol, except for the replacement of
the H2-9 and H2-10 methylene signals by two ortho-coupled
aromatic protons (δH‑10 7.89 and δH‑9 7.65, each 1H, d, J = 9.1
Hz) (Table 3). The presence of a double bond between C-9
and C-10 was corroborated by the HMBC cross-peaks of C-1a
(δC 134.9), C-5a (δC 128.7), C-8 (δC 129.2) with H-9 and C-1
(δC 118.7), C-4a (δC 126.0), and C-8a (δC 133.3) with H-10,
as well as by NOE interactions between H-8 (δH 7.59 s) and
H-9, and H-10 and H3-11 (δH 2.56).
Compound 9 (gerardiin I) was isolated as an amorphous
solid. The peak of the protonated molecule exhibited at m/z
503.2210 [M + H]+ in the HRESIMS suggested a molecular
formula of C34H30O4 (calcd C34H31O4, 503.2222). The 34
carbon signals, including five methylenes detected in the
JMOD spectrum, indicated that 9 is a dimer consisting of two
9,10-dihdyrophenanthrene units (Table 4). The 1H−1H COSY
spectrum defined two −CH2−CH2− fragments [δH 2.53 and
2.47, each 2H, m; 2.87, 2.59, 2.42 and 2.40, each 1H, m), two
pairs of ortho-coupled aromatic protons (δH 7.62 and 6.74,
each 1H, d, J = 8.4 Hz; δH 7.04 and 6.72, each 1H, d, J = 8.4
Hz), a pair of meta-coupled sp2 methines (δH 6.40 and 6.12,
Table 2. 1H (500 MHz) and 13C (125 MHz) NMR Data of Compounds 4−6 in DMSO-d6
4 5 6
position δH (J in Hz) δc, type δH (J in Hz) δc, type δH (J in Hz) δc, type
1 120.7, C 120.3, C 123.4, C
1a 138.9, C 138.9, C 138.8, C
2 154.3, C 153.7, C 153.9, C
3 6.72, d (8.4) 111.6, CH 6.71, d (8.4) 111.6, CH 7.00, d (8.6) 111.8, CH
4 7.10, d (8.4) 126.9, CH 7.13, d (8.4) 125.9, CH 7.26, d (8.6) 125.9, CH
4a 124.3, C 125.0, C 127.7, C
5 135.0, C 144.2, C 144.6, C
5a 128.0, C 124.8, C 124.4, C
6 7.06, d (2.1) 113.6, CH 6.92, d (2.2) 112.0, CH 6.94, d (2.2) 112.1, CH
7 155.4, C 155.4, C 155.8, C
8 6.92, d (2.1) 115.1, CH 6.56, d (2.2) 113.1, CH 6.58, d (2.2) 113.1, CH
8a 139.9, CH 139.4, C 139.8, C
9 2.59−2.65, m 29.9, CH2 2.48−2.55, m 30.5, CH2 2.51−2.57, m 30.4, CH2
10 2.59−2.65, m 25.0, CH2 2.59, m 25.4, CH2 2.61, m 25.3, CH2
2.49, m 2.51−2.57, m
11 2.13, s 11.7, CH3 2.12, s 11.7, CH3 2.22, s 12.0, CH3
OCH3-11
12 6.85, dd (17.3, 10.8) 138.0, CH 5.05, q (6.2) 64.2, CH 5.04, q (5.9) 64.2, CH
OCH3-12
13 5.74, d (17.4) 114.4, CH2 1.39, d (6.2) 25.6, CH3 1.40, d (5.9) 25.6, CH3
5.26, d (10.8)
14
1′ 4.88, d (7.4) 100.7, CH 4.81, d (7.1) 101.2, CH
2′ 3.23, m 73.3, CH 3.27, ma 73.4, CH
3′ 3.26, m 76.7, CH 3.27, ma 76.7, CH
4′ 3.14, dd (8.9, 8.3) 69.9, CH 3.16, m 69.8, CH
5′ 3.33, m 77.2, CH 3.31, m (overlaps with H2O) 77.0, CH
6′ 3.70, br d (11.4) 60.8, CH2 3.70, br d (11.4) 60.8, CH2
3.45, m 3.47, dd (11.4, 5.5)
aInterchangeable signals.
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each 1H, d, J = 2.0 Hz), and a further sequence of correlated
protons as follows: −CH−CH2−CHCH− (δH 5.19, 1H, d, J
= 9.3 Hz, 2.62 and 2.20, each 1H, m 5.76, 1H, m, and 6.77, 1H,
dd, J = 9.7 and 2.6 Hz). The latter structural portion was
incorporated into a cyclohexadiene ring and connected the two
phenanthrene units between C-6′−C-12, and C-13′−C-13, as
confirmed by the key HMBC correlations of C-12 (δC 30.8)
with H-6 (δH 6.12) and C-5, C-5′, and C-7′ (δC 142.5, 130.5,
and 152.3, respectively) with H-12 (δH 5.19) (Figure 2).
Further relevant HMBC correlations from C-5 (δC 142.5) and
C-12′ (δC 127.5) to H-13, from C-5′ to H-13′ (δH 5.76), and
from C-6′ (δC 123.9) to H-12′ (δH 6.77) and H-8′ (δH 6.56)
were also observed.
The substitution pattern of the monomers, excepting the
connection sites at C-5, C-5′, and C-6′, was identical with the
known effusol, which possesses a C-5 vinyl group. Thus, it is
postulated that 9 is biosynthesized from two effusol monomers
that are connected through their vinyl substituents. NOESY
cross-peaks of H-12 with H-4 and of H-4′ with H-12′ were in
agreement with these conclusions. While the planar structure
of gerardiin I (9) could be elucidated, the configuration of C-
12 still remained uncertain. The specific rotation value [α]D
25 of
Table 3. 1H (500 MHz) and 13C (125 MHz) NMR Data of
Compounds 7 and 8
7a 8b
position δH (J in Hz) δC, type δH (J in Hz) δC, type
1 120.5, C 118.7, C
1a 139.4, C 134.9, C
2 154.0, C 154.1, C
3 6.73, d (8.4) 111.6, CH 7.10, d (9.1) 115.8, CH
4 7.21, d (8.4) 126.2, CH 8.58, d (9.1) 128.1, CH
4a 124.6, C 126.0, C
5 144.0, C 138.2, C
5a 127.6,C 128.7, C
6 7.13, d (2.3) 113.6,
CHc
7.42, br s 131.3, CH
7 155.5, C 135.7, C
8 6.88, d (2.3) 113.6,
CHc
7.59, br s 129.2, CH
8a 139.8, C 133.3, C
9 2.54−2.64, m 30.6, CH2 7.65, d (9.1) 128.4, CH
10 2.54−2.64, m 25.3, CH2 7.89, d (9.1) 124.0, CH
11 2.13, s 11.7, CH3 2.56, s 11.4, CH3
OCH3-
11
12 5.07 m, (overlaps
with H2O)











14 2.51, s 21.3, CH3
1′ 4.85, d (7.5) 100.7, CH
2′ 3.24, m 73.3, CH
3′ 3.27, m 76.7, CH
4′ 3.18, m 69.7, CH
5′ 3.30, m 77.1, CH
6′ 3.68, br d (11.4) 60.7, CH2
3.49, m
aMeasured in DMSO-d6.
bMeasured in MeOD. cInterchangeable
signals.
Table 4. 1H (500 MHz) and 13C (125 MHz) NMR Data of
Compounds 9 and 10 in DMSO-d6
9 10
position δH (J in Hz) δC, type δH (J in Hz) δC, type
1 120.1, C 120.6, Ca
1a 139.2, C 139.3, C
2 153.3, C 153.7, C
3 6.74, d (8.4) 111.7, CH 6.68 (d, overlaps with
H-8′)
111.6, CH
4 7.62, d (8.4) 125.1, CH 7.03, d (7.8) 125.1, CH
4a 126.2, C 125.1, C
5 142.5, C 142.8, C
5a 125.1, C 125.9, C
6 6.12, d (2.0) 114.2, CH 6.76, d (2.2) 113.7, CH
7 154.3, C 155.2, C
8 6.40, d (2.0) 111.9, CH 6.57, d (2.2) 112.7, CH
8a 139.9, C 140.1, C
9 2.47, m 31.0, CH2 2.52−2.58, m 30.7, CH2
10 2.53, m 25.7, CH2 2.64, m 25.4, CH2
2.52, ma
11 2.15, s 11.7,
CH3
a
2.12, s 11.7, CH3
12 5.19, d (9.3) 30.8, CH 4.13, m 35.4, CH
13 2.62, m 30.0, CH2 3.17, m 30.7, CH2
2.20, m 2.59, ma
14
1′ 120.5, C 120.5, Ca
1a′ 138.6, C 133.7, C
2′ 153.6, C 153.8, C
3′ 6.72, d (8.4) 111.5, CH 6.72, d (8.1) 111.6, CH
4′ 7.04, d (8.4) 126.7, CH 7.05, d (8.1) 126.6, CH
4a′ 124.9, C 124.7, C
5′ 130.5, C 129.5, C
5a′ 124.3, C 124.5, C
6′ 123.9, C 119.4, C
7 152.3, C 151.9, C
8′ 6.56, s 113.4, CH 6.67 (s, overlaps with
H-3)
113.8, CH
8a′ 137.3, C 137.1, C
9′ 2.59, m 29.7, CH2 2.59, ma 29.7, CH2
2.42, m 2.44, m
10′ 2.87, m 25.3, CH2 2.80, m 25.3, CH2
2.40, m 2.42, m
11′ 2.14, s 11.9,
CH3
a
2.13, s 11.8, CH3
12′ 6.77, dd (9.7,
2.6)
127.5, CH 6.78, dd (9.8, 2.0) 127.0, CH
13′ 5.76, m 124.2, CH 5.93, br d (9.8) 132.3, CH
aInterchangeable signals.
Figure 2. 1H−1H COSY (red) and diagnostic HMBC (C→H)
correlations of 9.
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the compound was 0 (c 0.1, MeOH). When gerardiin I was
injected onto a chiral HPLC column, it eluted with two well-
separated peaks with a peak ratio area of 1:1. The peaks also
exhibited the same UV spectra, suggesting that 9 is a racemic
mixture, with the structure shown.
The protonated molecular ion peak of compound 10 at m/z
503.2213 [M + H]+ (calcd C34H31O4, 503.2222) in the
HRESIMS data provided the same molecular formula
(C34H30O4) as for 9. Careful analysis of the 1D NMR spectra
implied that compound 10 also comprises two effusol units
(Table 4). Based on the −CH(CH2)−CHCH− structural
portion (δH 4.13, 1H, m, 3.17 and 2.59, each 1H, m, 5.93, 1H,
br d, J = 9.8 Hz, 6.78, 1H, dd, J = 9.8 and 2.0 Hz), as defined
by the 1H−1H COSY spectrum, it was assumed that the effusol
monomers in 10 are connected via C-13′→ C-12 and C-13 →
C-6′ linkages. This hypothesis was supported by HMBC cross-
peaks of C-12 (δC 35.4) with H-6 (δH 6.76), C-5 (δC 142.8),
C-6′ (δC 119.4), and C-7′ (δC 151.9) with H-13 (δH 3.17), C-5
and C-5′ (δC 129.5) with H-13′ (δH 5.93), and C-5′ and C-6′
with H-12′ (δH 6.78). The specific optical rotation of 10 was
recorded as zero. When compound 10 was investigated by
HPLC using the same chiral stationary phase as in the case of
9, only one peak was observed. Thus, the structure of gerardiin
I (10) was assigned as shown.
Compound 11 (gerardiin K) was obtained as an amorphous
solid. According to its protonated molecular ion peak seen at
m/z 505.2375 [M + H]+ (calcd C34H33O4, 505.2379) in the
HRESIMS, the molecular formula of C34H32O4 was assigned to
this compound. The JMOD spectrum displayed 34 signals,
which suggested that compound 11 is also a phenanthrene
dimer (Table 5). The subunits were identified based on their
1D NMR data as effusol (15). The HMBC cross-peak of C-7
(δC 156.9) with H-12′ (δH 5.80), and a strong NOE from H-6
to H-12′ revealed that the monomers are linked through an
ether bond formed between the OH-7 group of one effusol
monomer and the vinyl side chain of the other effusol
molecule. The specific optical rotation of 11 was recorded as
zero. By HPLC investigation on chiral stationary phase, only
one peak was observed. Accordingly, the structure determined
for gerardiin K (11) is as shown.
Gerardiin L (12) was obtained as an amorphous solid. Its
HRESIMS provided the molecular formula C35H30O4 through
the presence of its protonated molecular ion peak at m/z
515.2213 [M + H]+ (calcd C35H31O4, 515.2222). The JMOD
spectrum of 12 displayed 35 carbon resonances, which
suggested that it is a dimer (Table 5). Since two vinyl groups
(δH 7.36, 5.74, and 5.33, each 1H, dd, J = 17.2, 10.7 Hz, 17.2,
1.3 Hz, and 10.7, 1.3 Hz, respectively, and 6.85, 5.65, and 5.13,
each 1H, dd, J = 17.4 and 10.8 Hz, 17.4 and 1.2 Hz, 10.8 and
1.2 Hz, respectively) were identified in the 1H NMR and
1H−1H COSY spectra, the phenanthrene monomers had to be
linked together in a different manner as in the cases of
gerardiins I−K (9−11). Moreover, the presence of a −CH2−
CH2− (δH 2.47 and 2.42, each 2H, m) subunit and three pairs
of ortho-coupled aromatic protons (δH 8.36 and 6.96, each 1H,
d, J = 9.1 Hz, 8.02 and 7.68, each 1H, d, J = 9.6 Hz, and 6.98
and 6.50, each 1H, d, J = 8.4 Hz) showed that 12 is composed
of a phenanthrene and a 9,10-dihydrophenanthrene unit.
These monomers could be characterized as effusol (15) and
dehydroeffusol (22) based on their 1H and 13C NMR chemical
shifts. However, the signals of H-8 and H-8′ were missing, and
a downfield-shifted, isolated methylene fragment appeared
instead at δH 4.58 and δC 22.8. In order to clarify the exact
structure, a series of 2D NMR experiments was recorded.
Considering the HMBC cross-peaks of C-7 and C-7′ (δC 152.8
and 154.1), C-8 and C-8′ (δC 122.9 and 127.5), and C-8a and
C-8a′ (δC 133.2 and 141.3) with the aforementioned
methylene (H2-14), it was concluded that the phenanthrene
monomers are connected through the CH2-14 group attached
to the corresponding carbons C-8 and C-8′ (Figure 3). These
data, combined with NOE interactions of H-4/H-12, H-6/H-
13, H-9/H-14, H-4′/H-12′, H-6′/H-13′, and H2-9′/H-14,
allowed the structure of 12 to be depicted as in Figure 3.
Table 5. 1H (500 MHz) and 13C (125 MHz) NMR Data of
Compounds 11 and 12 in MeOD
11 12
position δH (J in Hz) δC, type δH (J in Hz) δC, type
1 121.9, C 118.1, C
1a 140.2, C 133.1, Ca
2 155.1, C 153.1,C
3 6.56, d (8.6) 112.2, CH 6.96, d (9.1) 115.2, CH
4 7.02, d (8.6) 128.4, CH 8.36, d (9.1) 127.8, CH
4a 126.7, Ca 126.3, C
5 136.5, C 137.1, C
5a 128.2, C 124.9, C
6 6.25, d (1.9) 112.7, CH 7.22, s 118.6, CH
7 156.9, C 152.8, C
8 6.33, br s 115.6, CH 122.9, CH
8a 141.0, C 133.2, Ca
9 2.36−2.44, m 31.3, CH2 8.02, d (9.6) 125.3, CH
10 2.63, m 26.5, CH2 7.68, d (9.6) 123.2, CH
2.48, m
11 2.14, s 11.7, CH3 2.46, s 11.1, CH3
12 6.70, dd (17.4,
10.9)
139.8, CH 7.36, dd (17.2,
10.7)
143.4, CH





4.92, br d (10.9) 5.33, dd (10.7,
1.3)
14 4.58, s 22.8, CH
1′ 122.7, C 121.3, C
1a′ 141.4, C 140.0, C
2′ 155.5, C 154.7, C
3′ 6.79, d (8.6) 112.6,
CHa
6.50, d (8.4) 112.1, CH
4′ 7.04, d (8.6) 127.3, CH 6.98, d (8.4) 128.5, CH
4a′ 126.7, Ca 127.4, Ca
5′ 141.8, C 134.7, C
5a′ 128.6, C 128.7, C
6′ 6.94, d (2.1) 112.6,
CHa
7.00, s 112.7, CH
7 156.9, C 154.1, C
8′ 6.58, d (2.1) 114.7, CH 127.5, CHa
8a′ 141.3, C 141.3, C
9′ 2.65, m 31.8, CH2 2.42, m 27.2, CH2
2.52, m
10′ 2.98, br d (14.6) 27.2, CH2 2.47, m 26.4, CH2
2.30, m
11′ 2.27, s 12.1, CH3 2.09, s 11.6, CH3
12′ 5.80, q (6.2) 72.1, CH 6.85, dd (17.4,
10.8)
140.4, CH
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Besides the new compounds, gerardiins A−L (1−12), 11
known phenanthrenes, the monomers effusol (13) and




drophenanthrene,12 effususol A,13 2,7-dihydroxy-5-hydroxy-
methyl-1-methyl-9,10-dihydrophenanthrene,9 jinflexin C,14 the
diphenanthrene effususin A (15), 1-O-p-coumaroyl-3-O-
feruloyl-glycerol,15 and the flavones apigenin and luteolin,16
were also isolated from J. gerardii. Their identifications were
made by analysis of their HRESIMS and 1D and 2D NMR
spectra and by comparison of their 1H and 13C NMR chemical
shifts with literature values. In this report, complete 1H and




dihydrophenanthrene, effususol A, 2,7-dihydroxy-5-hydroxy-
methyl-1-methyl-9,10-dihydrophenanthrene, effususin A, and
1-O-p-coumaroyl-3-O-feruloyl-glycerol measured in different
solvents than those previously reported; these data are listed in
the Experimental Section. All compounds were isolated for the
first time from the plant. All of the known compounds, with
the exception of 1-O-p-coumaroyl-3-O-feruloyl glycerol, were
isolated previously from other Juncus species.
Gerardiin A (1) and gerardiin B (2) are substituted with a
methoxymethylene group at C-1 (1) or C-7 (2). The structure
of compound 1 is very similar to that of effusol, with the only
difference being the presence of a methoxy group at C-11.
Gerardiins C (3) and D (4) are glycosides of effusol,
substituted with a D-glucose unit at C-2 (3) or C-7 (4),
respectively. Gerardiins F (6) and G (7) are also substituted
with a D-glucose moiety. Gerardiin E (5) contains a
hydroxyethyl group at C-5, instead of a vinyl group. The
only difference between gerardiin H (8) and juncunol, isolated
previously from other Juncus species (J. acutus, J. ef fusus, J.
roemerianus, J. subulatus),10,17−19 is the presence of an
unsaturated B ring in the former phenanthrene.
Phenanthrenoid dimers represent a rare class of secondary
metabolites; to date, less than 20 have been reported from
species in the plant family Juncaceae. In gerardiins I (9) and J
(10), the two effusol monomers are connected through their
vinyl groups. Gerardiin K (11) is composed of two effusol
monomers that are joined through an ether bond, while in
gerardiin L (12) an effusol and a dehydroeffusol unit are
attached via a C−C linkage formed between C-8−C-8′. The
individual monomers [effusol (13) and dehydroeffusol (14)]
were also isolated from the plant.
In order to gain insight into the biological effects of the
isolated phenanthrenes, 4T1 mouse breast cancer cells were
treated with the isolated compounds, and changes in the
viability and impedance were assessed, which reflects
proliferation, degree of adhesion, spreading, and viability of
the cells. At a concentration of 20 μM, compounds 1−8
(gerardiin A−H) had no cytotoxic effects on 4T1 cells, as
assessed by an MTT assay (Figure S73A, Supporting
Information) or impedance measurements (Figure S73B,
Supporting Information).
In contrast to this, the viability of 4T1 cells was reduced
significantly in a concentration-dependent manner in response
to compounds 9−12 (gerardiins I−L) (Figure S74, Supporting
Information). The effect of these phenanthrenes was
comparable to that of doxorubicin, which was applied as a
positive control to measure cytotoxicity. Since all these
compounds are dimers of effusol (13) (compounds 9−11)
or of effusol and dehydroeffusol (14) (compound 12), the
cytotoxic effects of the monomers and dimers in both mouse
and human tumor cells and in a nontumor cell line (D3) were
compared. Besides the aforementioned phenanthrenes, effusu-
sin A (15) was also included in this study, since it is also a
dimer of effusol (Figure S74, Supporting Information).
The present results show unequivocally that the dimeric
compounds 9−12 and 15 comprising effusol (13) and
dehydroeffusol (14) monomers are cytotoxic to both tumor
and nontumor cell lines, while the monomers (13, 14) alone
displayed no or very low cytotoxicity (Figure S74, Supporting
Information). Among the diphenanthrenes tested, effususin A
(15) exerted the lowest cytotoxicity, while gerardiins I−L (9−
12) proved to be the most active. Indeed, moderate toxicity of
effususin A (15) in A2780 human ovarian cancer cells was
reported by Buś et al.8 Impedance measurements were in line
with the results of the MTT assay, indicating a concentration-
dependent toxicity of the dimers (Figure S76, Supporting
Information).
IC50 values of both 9 and 10 were below 10 μM in the two
tested tumor cell lines (Table 6). In the case of compound 11,
Figure 3. 1H−1H COSY (red) and diagnostic HMBC (C → H)
correlations of 12.
Table 6. IC50 Values
a and Their 95% Confidence Intervals
[95% C.I.] for Compounds 9−12
cell line
compound MDA-MB-231 4T1
9 8.0 [7.3−8.8] 7.8 [6.5−9.5]
10 6.6 [6.2−7.1] 5.6 [5.1−6.1]
11 >10 8.1 [7.7−8.6]
12 7.3 [6.7−7.9] >10
doxorubicin 0.8 [0.7−0.9] 3.4 [3.1−3.7]
aHalf-maximal inhibitory concentration (μM), n = 6−8.
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the concentration that caused 50% inhibition of cell viability
was lower than 10 μM only in the mouse (4T1) (IC50 8.1
μM), but not in the human breast cancer (MDA-MB-231) cell
line (10.1 μM). On the other hand, compound 12 was more
cytotoxic (IC50 7.3 μM) to the human breast cancer cells (IC50
was 11.7 μM on 4T1 cells). D3 endothelial cells were the less
sensitive to these diphenanthrenes, all of them having IC50
values above 10 μM (21.6 μM for 9, 15.7 μM for 10, 10.6 μM
for 11, and 13.7 μM for 12, respectively) (Table S1,
Supporting Information).
Considering the already known isolated phenanthrenes, only
juncusol (in MTT and impedance assays) and jinflexin C (in
impedance measurements) displayed moderate cytotoxicity,
while compressin A, 7-hydroxy-2-methoxy-1-methyl-5-vinyl-
9,10-dihydrophenanthrene, 2-hydroxy-7-hydroxymethylene-1-
methyl-5-vinyl-9,10-dihydrophenanthrene, 2,7-dihydroxy-5-
formyl-1-methyl-9,10-dihydrophenanthrene, effususol A, and
2,7-dihydroxy-5-hydroxymethyl-1-methyl-9,10-dihydrophenan-
threne were not cytotoxic in 4T1 cells at the concentration of
20 μM (Figure S75, Supporting Information). The present
results are in agreement with previous findings that
demonstrated the antiproliferative activity of juncusol against
HeLa cervical cancer cells.20
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
determined in MeOH at ambient temperature using a PerkinElmer
341 polarimeter. NMR spectra were recorded in MeOD and DMSO-
d6 on a Bruker Avance DRX 500 spectrometer at 500 MHz (
1H) and
125 MHz (13C). The signals of the deuterated solvents were taken as
references. The chemical shift values (δ) were given in ppm, and
coupling constants (J) are in Hz. Two-dimensional (2D) experiments
were performed with standard Bruker software. In the COSY, HSQC,
and HMBC experiments, gradient-enhanced versions were used. The
HRMS were acquired on a Thermo Scientific Q-Exactive Plus
Orbitrap mass spectrometer equipped with ESI ion source in the
positive ionization mode. The resolution was over 1 ppm. The data
were acquired and processed with MassLynx software.
Vacuum-liquid chromatography (VLC) was carried out on silica gel
(15 μm, Merck); LiChroprep RP-18 (40−63 μm, Merck) stationary
phase was used for reversed-phase VLC; column chromatography
(CC) was performed on polyamide (MP Biomedicals). Medium-
pressure liquid chromatography (MPLC) was processed with a
Combi Flash Rf+ Lumen instrument (Teledyne Isco) on a reversed-
phase RediSep Rf HP Gold (50 g) column. Preparative thin-layer
chromatography (prep. TLC) was performed on silica gel 60 F254
plates (Merck) and on reversed-phase silica gel 60 RP-18 F254 plates
(Merck). Sephadex LH-20 (25−100 μm, Sigma-Aldrich) was used for
gel filtration. HPLC was carried out on a Waters HPLC, using normal
(Phenomenex Luna silica, 3 μm 100 A) and reversed-phase
[Phenomenex, Kinetex 5 μm C18 100A and LiChrospher
LiChroCART 250-4 RP-18e (5 μm)] columns. For the investigation
of compounds with a chiral carbon atom, a Lux amylose-1 column
(250 × 21.2 mm) (Phenomenex, USA) was used with cyclohexane−
isopropanol (85:15) as mobile phase. All solvents used for CC were of
at least analytical grade (VWR Ltd., Hungary).
Plant Material. Juncus gerardii (whole plant, 3.6 kg) was collected
during the flowering period in June 2017, near Moŕahalom, Hungary
(GPS coordinates: 46°12.017″ N; 019°58.955″ E). Botanical
identification of the plant material was performed by one of the
authors (L.B., Department of Plant Biology, University of Szeged,
Szeged, Hungary), and a voucher specimen (No. 881) has been
deposited at the Department of Pharmacognosy, University of Szeged,
Szeged, Hungary.
Extraction and Isolation. The air-dried whole plant of J. gerardii
(3.6 kg) was percolated with MeOH (60 L) at room temperature.
The crude methanolic extract was concentrated under reduced
pressure (421 g) and subjected to solvent−solvent partitioning with
n-hexane (4 × 1 L), chloroform (4 × 1 L), and ethyl acetate (4 × 1
L), respectively.
The concentrated chloroform-soluble fraction (52 g) was separated
by polyamide open column chromatography with a gradient system of
MeOH−H2O {2:3 (A), 3:2 (B), 2:1 [10 L (C), 8 L (D), and 8 L (E),
respectively], each eluent was collected as a fraction}. The fraction
obtained from the polyamide column with MeOH−H2O (3:2, 12 g)
was subjected to VLC on silica gel, with a gradient system of
cyclohexane−EtOAc−MeOH [from 98:2:0 to 1:1:1 (1500 mL/
eluent) and finally with MeOH; volume of collected fractions was 100
mL], to yield 16 major fractions (B/1−16). The fractions were
combined according to their TLC patterns. Fractions B/1−3 (45.5,
21.5, and 38.9 mg, respectively) were purified using Sephadex LH-20
gel chromatography with CH2Cl2−MeOH (1:1) as eluent, to yield
compounds 8 (1.2 mg) and compressin A (5.8 mg) from B/1, 7-
hydroxy-2-methoxy-1-methyl-5-vinyl-9,10-dihydrophenanthrene (6.8
mg) from B/2, and compound 2 (11.8 mg) from B/3. Fraction B/
4 (1.64 g) was separated by reversed-phase (RP) MPLC, by using a
gradient system of MeOH−H2O [from 1:1 to 1:0 (40 mL/min);
volume of collected fractions was 20 mL], to yield eight subfractions
(B/4/1−8). Subfractions B/4/2 and B/4/4 were pure for compounds
13 (1.3 g) and juncusol (185 mg), respectively. Fraction B/6 (494.0
mg) was also separated by RP-MPLC, using a gradient system of
MeOH−H2O [from 1:1 to 1:0 (40 mL/min); volume of collected
fractions was 20 mL)], to afford eight subfractions (B/6/1−8).
Fractions B/6/2 (31.8 mg) and B/6/5 (42.6 mg) were purified by
prep. TLC on silica gel using cyclohexane−EtOAc−EtOH (20:10:1)
as solvent system, to yield compounds 1 (2.1 mg) and 14 (3.9 mg).
Subfraction B/6/6 contained 2-hydroxy-7-hydroxymethylene-1-meth-
yl-5-vinyl-9,10-dihydrophenanthrene (109 mg). Fraction B/7 (771.1
mg) was separated by RP-MPLC with a gradient system of MeOH−
H2O [from 1:1 to 1:0 (40 mL/min); volume of collected fractions
was 20 mL] to yield 11 subfractions (B/7/1−11). Fraction B/7/2
(179.5 mg) was purified by Sephadex LH-20 gel chromatography
using CH2Cl2−MeOH (1:1) as solvent system to afford five
subfractions (B/7/2/1−5). Further purification of subfraction B/7/
2/4 by normal-phase (NP) HPLC under gradient conditions, using
cyclohexane−EtOAc (9:1 to 1:9 in 10 min at a flow rate of 1.5 mL/
min) as mobile phase, yielded two fractions (tR = 7.5 min and tR = 7.9
min), which were purified by preparative TLC on silica gel using
cyclohexane−EtOAc−EtOH (20:10:1) as solvent system, to yield 2,7-
dihydroxy-5-formyl-1-methyl-9,10-dihydrophenanthrene (3.1 mg)
and 2,7-dihydroxy-5-hydroxymethyl-1-methyl-9,10-dihydrophenan-
threne (2.0 mg). Fraction B/7/6 (8.6 mg) was purified by prep.
TLC on silica gel using cyclohexane−EtOAc−EtOH (20:10:1) as
mobile phase to yield compound 11 (6.2 mg).
Fractions B/8 (63 mg) and B/9 (230.2 mg), B/12 (421.3 mg) and
B/14 (548.6 mg) were separated by Sephadex LH-20 gel
chromatography using CH2Cl2−MeOH (1:1) as solvent system to
yield compound 12 (5.5 mg, from B/8), jinflexin C (8.2 mg, from B/
9/2), apigenin (18.7 mg, from B/12/2), and luteolin (22.8 mg, from
B/14/2). Fraction B/10 (154.5 mg) was purified by Sephadex LH-20
gel chromatography using CH2Cl2−MeOH (1:1) as solvent system to
afford six subfractions (B/10/1−6). Fraction B/10/4 (30.1 mg) was
purified by preparative TLC on silica gel using CH2Cl2−MeOH (9:1)
as solvent system to yield compound 5 (9.2 mg). Fraction B/11
(474.1 mg) was purified by Sephadex LH-20 gel chromatography
using CH2Cl2−MeOH (1:1) as solvent system to afford four
subfractions (B/11/1−4). Fractions B/11/2 (112.2 mg) and B/11/
3 (54.6 mg) were further purified by preparative TLC on silica gel
using CH2Cl2−MeOH (9:1) as solvent system, to yield 1-O-p-
coumaroyl-3-O-feruloyl-glycerol (9.2 mg) and 2,7-dihydroxy-5-
hydroxymethyl-1-methyl-9,10-dihydrophenanthrene (11.8 mg).
The fraction obtained from the polyamide column with MeOH−
H2O 2:1 (3 g) was subjected to VLC on silica gel with a gradient
system of cyclohexane−EtOAc−MeOH [from 95:5:0 to 1:1:1 (200
mL/eluent), and finally with MeOH; the volumes of the collected
fractions were 50 mL], to yield six major fractions (D/1−6). The
fractions were combined according to their TLC patterns. Fraction
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D/4 (130.1 mg) was purified by Sephadex LH-20 gel chromatography
applying CH2Cl2−MeOH (1:1) as solvent system to afford four
subfractions (D/4/1−4). Subfraction D/4/4 (15.8 mg) was purified
by preparative TLC on silica gel using CH2Cl2−MeOH (9:1) as
solvent system to yield compound 9 (5.9 mg). Fraction D/5 (124
mg) was purified by Sephadex LH-20 gel chromatography using
CH2Cl2−MeOH (1:1) as solvent system to afford four subfractions
(D/5/1−4). Further purification of subfraction D/5/3 by reversed-
phase HPLC under gradient conditions, using CH3CN−H2O (from
55:44 to 7:3 in 11 min as mobile phase, flow rate 1.5 mL/min),
resulted in the isolation of compound 15 (tR = 8.1 min, 4.6 mg).
Fraction D/5/4 (20.1 mg) was purified by prep. TLC on silica gel
using CH2Cl2−MeOH (95:5) as solvent system, to yield compound
10 (4.0 mg).
The concentrated ethyl acetate-soluble fraction (37 g) was
separated by VLC on silica gel with a gradient system of CHCl3−
MeOH [from 98:2 to 6:4 (1500 mL/eluent), and finally with MeOH;
volume of collected fractions were 100 mL], to yield 15 major
fractions (F/1−15). The fractions were combined according to their
TLC patterns. Fraction F/8 (705.3 mg) was purified by Sephadex
LH-20 gel chromatography using CH2Cl2−MeOH (1:1) as eluent
and then by RP-TLC on RP silica gel using MeOH−H2O (1:1) as
mobile phase. Further purification of subfraction F/8/2/1 by RP-
HPLC under gradient conditions, using CH3CN−H2O (from 21:79
to 26:74 in 10 min as mobile phase, flow rate 1.5 mL/min), resulted
in the isolation of compounds 3 (tR = 8.35 min, 1.8 mg) and 4 (tR =
9,4 min, 2.0 mg). Fraction F/10 (720.4 mg) was separated by
Sephadex LH-20 gel chromatography using CH2Cl2−MeOH (1:1) as
eluent and RP-TLC on RP silica gel using MeOH−H2O (2:3) as
solvent system. Further purification of subfraction F/10/2/1 by RP-
HPLC under gradient conditions, using CH3CN−H2O (from 1:9 to
35:65 in 12 min, flow rate 1.5 mL/min) as mobile phase, afforded
compounds 6 (tR = 11.3 min, 6.8 mg) and 7 (tR = 12.1 min, 1.8 mg).
Gerardiin A (1): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 251.1068 [M + H − CH3OH]+
(calcd for C17H18O2, 251.1072).
Gerardiin B (2): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 249.1275 [M + H − CH3OH]+
(calcd for C18H17O, 249.1279).
Gerardiin C (3): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 437.1565 [M + Na]+ (calcd for
C23H26O7Na, 437.1576).
Gerardiin D (4): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 437.1564 [M + Na]+ (calcd for
C23H26O7Na, 437.1576).
Gerardiin E (5): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 253.1226 [M + H − H2O]+
(calcd for C17H17O2, 253.1229).
Gerardiin F (6): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 455.1671 [M + Na]+ (calcd for
C23H28O8Na, 455.1682).
Gerardiin G (7): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 455.1675 [M + Na]+ (calcd for
C23H28O8Na, 455.1682).
Gerardiin H (8): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 249.1274 [M + H]+ (calcd for
C18H17O, 249.1279).
Gerardiin I (9): amorphous solid; [α]D
25 0 (c 0.1, MeOH); 1H and
13C NMR data, see Tables 1 and 2; (+)-HRESIMS m/z 503.2210 [M
+ H]+ (calcd for C34H31O4, 503.2222).
Gerardiin J (10): amorphous solid; [α]D
25 0 (c 0.1, MeOH); 1H and
13C NMR data, see Tables 1 and 2; (+)-HRESIMS m/z 503.2213 [M
+ H]+ (calcd for C34H31O4, 503.2222).
Gerardiin K (11): amorphous solid; [α]D
25 0 (c 0.1, MeOH); 1H and
13C NMR data, see Tables 1 and 2; (+)-HRESIMS m/z 505.2375 [M
+ H]+ (calcd for C34H33O4, 505.2379).
Gerardiin L (12): amorphous solid; 1H and 13C NMR data, see
Tables 1 and 2; (+)-HRESIMS m/z 515.2213 [M + H]+ (calcd for
C35H31O4, 515.2222).
Compressin A: 1H NMR (500 MHz, methanol-d4) δ 7.53 (1H, d, J
= 8.7 Hz, H-4), 6.79 (1H, dd, J = 18.0, 11.4 Hz, H-12), 6.70 (1H, d, J
= 8.7 Hz, H-3), 6.63 (1H, s, H-8), 5.42 (1H, d, J = 11.4 Hz, H-13a),
5.12 (1H, d, J = 18.0 Hz, H-13b), 3.81 (3H, s, OCH3), 2.66 (2H, m,
H-10), 2.55 (2H, m, H-9), 2.21 (3H, s, CH3), 2.18 (3H, s, CH3).
7-Hydroxy-2-methoxy-1-methyl-5-vinyl-9,10-dihydrophenan-
threne: 1H NMR (500 MHz, methanol-d4) δ 7.33 d (1H, d, J = 8.6
Hz, H-4), 6.93 (1H, dd, J = 17.5, 10.9 Hz, H-12), 6.86 (1H, d, J = 2.4
Hz, H-6), 6.78 (1H, d, J = 8.6 Hz, H-3), 6.65 (1H, d, J = 2.4 Hz, H-
8), 5.64 (1H, d J = 17.4 Hz, H-13a), 5.20 (1H, d, J = 10.9 Hz, H-
13b), 3.83 (3H, s, OCH3), 2.68 (2H, m, H-10), 2.62 (2H, m, H-9),
2.20 (3H, s, CH3).
2-Hydroxy-1-methyl-7-hydroxymethylene-5-vinyl-9,10-dihydro-
phenanthrene: 1H NMR (500 MHz, methanol-d4) δ 7.39 (1H, s, H-
6), 7.28 (1H, d, J = 8.4 Hz, H-4), 7.14 (1H, s, H-8), 6.95 (1H, dd, J =
17.4, 10.9 Hz, H-12), 6.67 (1H, d, J = 8.4 Hz, H-3), 5.70 (1H, d, J =
17.4, H-13a), 5.22 (1H, d, J = 10.9 Hz, H-13b), 4.59 (2H, s, H-14),
2.12 (3H, s, CH3);
13C NMR (125 MHz, methanol-d4) δ 155.8 (C-2),
140.9 (C-1a), 140.4 (C-12), 140.0 (C-7), 135.9 (C-5), 128.9 (C-4),
126.6 (C-4a), 126.5 (C-8), 126.2 (C-6), 122.1 (C-1), 113.8 (C-13),
112.4 (C-3), 65.1 (C-14), 31.1 (C-9), 26.6 (C-10), 11.8 (CH3-1).
2,7-Dihydroxy-5-formyl-1-methyl-9,10-dihydrophenanthrene:
1H NMR (500 MHz, methanol-d4) δ 9.95 (1H, s, H-12), 7.14 (1H, d,
J = 2.5 Hz, H-6), 6.97 (1H, d, J = 2.5 Hz, H-8), 6.77 (1H, d, J = 8.3
Hz, H-4), 6.74 (1H, d, J = 8.3 Hz, H-3), 2.78 (2H, m, H-10), 2.72
(2H, m, H-9), 2.24 (3H, s, CH3);
13C NMR (125 MHz, methanol-d4)
δ 194.6 (C-12), 157.3 (C-7), 156.9 (C-2), 142.9 (C-8a), 140.3 (C-
1a), 135.1 (C-5), 123.1 (C-1), 129.7 (C-4), 124.4 (C-4a), 120.9 (C-
8), 113.1 (C-3), 112.7 (C-7), 30.4 (C-9), 26.4 (C-10), 11.8 (CH3-1).
Effususol A: 1H NMR (500 MHz, DMSO-d6) δ 6.87 (1H, d, J = 8.3
Hz, H-4), 6.78 (1H, d, J = 2.3 Hz, H-6), 6.73 (1H, d, J = 8.3 Hz, H-
3), 6.60 (1H, d, J = 2.0 Hz, H-8), 4.70 (1H, q, J = 6.1 Hz, H-12), 2.86
(3H, s, OCH3), 2.76 (1H, m, H-10a), 2.62 (1H, m, H-9a), 2.42 (1H,
m, H-9b), 2.37 (1H, m, H-10b), 2.12 (3H, s, CH3), 1.48 (3H, d, J =
6.2 Hz, CH3);
13C NMR (125 MHz, DMSO-d6) δ 155.7 (C-7), 153.8
(C-2), 140.8 (C-5), 139.6 (C-8a), 139.0 (C-1a), 126.2 (C-5a), 125.7
(C-4), 124.5 (C-4a), 120.51 (C-1), 113.6 (C-8), 111.6 (C-3), 111.3
(C-6), 74.4 (C-12), 55.0 (OCH3-12), 30.4 (C-9), 25.4 (C-10), 23.1
(C-13), 11.75 (CH3-1).
2,7-Dihydroxy-1-methyl-5-hydroxymethyl-9,10-dihydrophenan-
threne: 1H NMR (500 MHz, DMSO-d6) δ 7.26 (1H, d, J = 8.5 Hz,
H-4), 6.87 (1H, d, J = 2.3 Hz, H-6), 6.70 (1H, d, J = 8.5 Hz, H-3),
6.58 (1H, d, J = 2.3 Hz, H-8), 4.49 (2H, s, H-12), 2.55 (2 × 2H, brs,
H-9, H-10), 2.11 (3H, s, CH3);
13C NMR (125 MHz, DMSO-d6) δ
155.1 (C-7), 153.7 (C-2), 139.3* (C-5), 139.1* (C-8a), 138.4 (C-
1a), 125.7 (C-4), 125.7 (C-5a), 125.2 (C-4a), 120.3 (C-1), 114.8 (C-
6), 113.2 (C-8), 111.6 (C-3), 62.1 (C-12), 30.2 (C-9), 25.3 (C-10),
11.7 (CH3-1) (*interchangeable signals).
Effususin A (15): 1H NMR (500 MHz, DMSO-d6) δ 7.15 (1H, s,
H-4, H-4′), 6.90 (1H, dd, J = 17.3, 10.8 Hz, H-12, H-12′), 6.79 (1H,
d, J = 1.7 Hz, H-6, H-6′), 6.63 (1H, d, J = 1.6 Hz, H-8, H-8′), 5.54
(1H, d, J = 17.4 Hz, H-13a, H-13a′), 5.06 (1H, d, J = 10.8 Hz, H-13b,
H-13b′), 2.60 (2 × 2H, m, H-9, H-9′, H-10, H-10′), 2.18 (3H, s,
CH3-1, CH3-1′); 13C NMR (125 MHz, DMSO-d6) δ 157.3 (C-2, C-
2′), 154.7 (C-7, C-7′), 139.8 (C-8a, C-8a′), 138.9 (C-12, C-12′),
135.9 (C-1a, C-1a′), 134.5 (C-5, C-5′), 128.5 (C-4, C-4′), 126.7 (C-
5a, C-5a′), 125.7 (C-3, C-3′), 122,3 (C-1, C-1′), 114.3 (C-8, C-8′),
112.6 (C-13, C-13′), 112.1 (C-6, C-6′), 30.2 (C-9, C-9′), 25.5 (C-10,
C-10′), 12.7 (C-11, C-11′).
1-O-p-Coumaroyl-3-O-feruloyl-glycerol: 1H NMR (500 MHz,
DMSO-d6) δ 7.58 (1H, d, J = 15.9 Hz), 7.57 (1H, d, J = 15.9 Hz),
7.53 (1H, d, J = 8.6 Hz), 7.31 (1H, d, J = 1.2 Hz), 7.10 (1H, dd, J =
8.2, 1.2 Hz), 6.78 (1H, d, J = 8.2 Hz), 6.77 (2 × 1H, d, J = 8.6 Hz),
6.48 (1H, d, J = 15.9 Hz), 6.39 (1H, d, J = 15.9 Hz), 4.15 (2H, d, J =
5.1 Hz), 4.11 (2H, m), 4.01 (1H, m), 3.80 (3H, s, OCH3);
13C NMR
(125 MHz, DMSO-d6) δ 2 × 166.6, 160.2, 149.7, 148.0, 145.1, 145.4,
130.4, 125.4, 124.9, 123.3, 115.9, 115.6, 114.1, 113.8, 111.1, 66.4,
65.1, 55.7.
Cell Culture and Cytotoxicity Testing. 4T1 (mouse triple-
negative breast cancer cells) were cultured in RPMI (Roswell Park
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Memorial Institute) 1640 medium supplemented with 5% fetal bovine
serum (FBS) (both from Thermo Fisher Scientific, Waltham, MA,
USA). MDA-MB-231 (human triple-negative breast cancer cells,
abbreviated as MDA) were cultured in DMEM (Dulbecco’s modified
Eagle’s medium, Thermo Fisher Scientific) + 5% FBS. D3 (hCMEC/
D3 human cerebral microvascular endothelial cells) were kept in rat
tail collagen-coated dishes in EBM-2 (endothelial basal medium-2,
Lonza, Basel, Switzerland) complemented with 2% FBS and an EGM-
2MV kit (Lonza).
Viability and impedance measurements were performed in the log
growth phase of tumor cells and in the stationary phase of endothelial
cells.
For the MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazo-
lium bromide) viability assay, cells were plated in 96-well plates
(Corning, Corning, NY, USA). The seeding density of the cells was
5000/well (for 4T1 or MDA cells) or 25 000/well (for D3 cells).
After 48 h, half of the medium was replaced with serum-free medium,
containing the test compounds in a final concentration of 10 or 20
μM. Control wells received solvent (DMSO) in up to a 0.2%
concentration. After 48 h, MTT reagent (Sigma-Aldrich, St. Louis,
MO, USA) was added to the cells in a final concentration of 2.5 mg/
mL. After incubation at 37 °C for 30 min, acidified isopropanol
solution was added to each well. Absorbance was measured at 595 nm
with a FLUOstar OPTIMA microplate reader (BMG LABTECH,
Offenburg, Germany). Doxorubicin was used as a positive control, at a
concentration of 10 μM.
For impedance measurements, cells were plated in 96-well E-plates
having microelectrodes integrated on the bottom (ACEA Biosciences,
San Diego, CA, USA) and allowed to attach onto the electrode
surface for 48 h. Afterward, cells were treated with the test
compounds as described above. Electrical impedance was recorded
every 30 min for 48 h using an xCELLigence real-time cell analysis
(RTCA) instrument (ACEA Biosciences). Cell index was automati-
cally calculated by the software of the instrument.
For determining IC50 values, nine-step, 2-fold serial dilutions of the
test compounds were applied, starting from 100 μM. Cells were
treated for 48 h, and viability was measured with the MTT assay, as
described above. Half-maximum inhibitory concentrations (IC50)
were calculated via nonlinear dose−response curve fitting by the
log(inhibitor) vs response (variable slope) model of GraphPad Prism
5.01 (GraphPad Software, San Diego, CA, USA) by using automatic
outlier elimination at Q = 1.0.
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László Bakacsy − Department of Plant Biology, University of
Szeged, 6726 Szeged, Hungary
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